News & Updates

The novel highly selective mineralocorticoid receptor blocker esaxerenone holds promise in the treatment of nocturnal hypertension, yielding substantial reductions in night-time blood pressure (BP), especially in Japanese patients with a riser pattern, as well as in N-terminal pro B-type natriuretic peptide (NT-proBNP) levels, according to a post hoc analysis of a phase III study.

A peak systolic blood pressure (SBP) at clinical exercise testing that is slightly lower than the predicted value appears predictive of future cardiovascular disease (CVD) and mortality, suggests a study. Higher peak SBP, however, is not associated with such risks.

In individuals with psoriatic arthritis (PsA) who have inadequate response or intolerance to ≥1 csDMARD*, the monoclonal antibody risankizumab significantly improved manifestations of PsA, according to the 24-week findings of the phase III KEEPsAKE 1 trial.

Levels of prostate specific antigen (PSA) mRNA in circulating tumour cells can be used alongside serum PSA protein levels to refine the assessment of disease progression in patient with metastatic castration-resistant prostate cancer (mCRPC), a new study has found.

Patients with hypothyroidism who develop COVID-19 have a lower mechanical ventilation requirement and are less likely to die in the hospital, as reported in a study.

The prevalence of depression is relatively high among children, adolescents, and adults with hidradenitis suppurativa (HS), a chronic inflammatory skin disorder, according to a study, which also notes the importance of periodic screening for depression.